Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975669 | 0.84 | ALDH1A1 (0.47) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21839631 | 0.84 | ADORA3 (0.50) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL21839468 | 0.84 | ADORA3 (0.42) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL26721158 | 0.83 | ADORA3 (0.43) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL24618971 | 0.82 | ADORA3 (0.46) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30394639 | 0.82 | NT5E (0.41) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21839756 | 0.79 | ADORA1 (0.45) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL28910208 | 0.79 | ADORA3 (0.36) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL22975448 | 0.79 | ADORA3 (0.39) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL21839695 | 0.79 | NT5E (0.48) | NT5EADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325938-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210047359-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325938-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA1 23/4885 |
| US-20210047359-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.